Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

about

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia.

P2860

Q35687553-AD41B793-E754-4378-BA46-595BA04D2A61

P2860

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q38222824

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

@en

type

Item

label

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

@en

prefLabel

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

@en

P1476

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

@en

P2093

Jonathan Friedberg

http://www.w3.org/2001/XMLSchema#string

Sudy Jahangiri

http://www.w3.org/2001/XMLSchema#string

P2860

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk

p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes

BLNK: a central linker protein in B cell activation

Activation of Src-like protein-tyrosine kinase Lyn and its association with phosphatidylinositol 3-kinase upon B-cell antigen receptor-mediated signaling

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

A double-edged kinase Lyn: a positive and negative regulator for antigen receptor-mediated signals

P304

367-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2014.929663

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul M Barr

P577

2014-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24960458

http://www.w3.org/2001/XMLSchema#string

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

about

P2860

P2860

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698